This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion’s Magsense™ technology, which provide specific targeting of cancerous cells,
Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead nanoparticle
MELBOURNE, Australia, Dec. 17, 2018 /PRNewswire/ — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster “Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles” at the 2018
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
This article represents the viewpoint of management. When MagSense technology reaches the clinic, it will join a distinguished pantheon of time-honored cancer detection imaging methods,
The ASCO 2018 Annual Meeting abstract, “Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry” is now available
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding out more,
Citing increasing demand from doctors to assess diseases close up, the Australian investment news service Stockhead has included Imagion Biosystems (ASX:IBX) among “Ten ASX medical imaging
Imagion Biosystems’ abstract “Detection of HER2+ tumor cells using MagSense® nanoparticles: safety and sensitivity” has been accepted for the 2018 AACR meeting under the organization’s
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance